Tresiba Missed-Dose Protocol: What to Do When You Skip Insulin Degludec

The FDA-Labeled Missed-Dose Rule

The prescribing information for Tresiba states a simple protocol: if a dose is missed, inject it as soon as you realize, then resume your normal once-daily schedule 1. The minimum interval between two consecutive injections is 8 hours. That 8-hour floor exists because stacking two full doses within a few hours could drive glucose dangerously low, even with degludec's flat pharmacokinetic profile.

Here is a practical decision tree. If you remember your missed dose within roughly 12 hours, take it immediately and keep your next dose at its usual time (provided 8 hours will have passed). If you remember your missed dose and the next scheduled dose is fewer than 8 hours away, skip the missed dose entirely and take the next one on time. Do not take two doses to make up for one. This instruction applies to both U-100 and U-200 concentrations of Tresiba, as the pharmacokinetic behavior is bioequivalent at equal unit doses 1.

One reason this protocol is simpler than those for older basal insulins is degludec's pharmacology. The drug forms multi-hexamer chains in subcutaneous tissue that dissociate slowly, producing a steady release of monomers into the bloodstream over more than 42 hours 2. That depot effect means glucose coverage does not vanish the moment a dose is late.

Why Degludec Tolerates Dosing Gaps Better Than Other Basals

Glargine U100 (Lantus) has an effective duration of roughly 20 to 24 hours. NPH insulin lasts 12 to 16 hours. A missed dose of either can leave a patient without meaningful basal coverage within half a day. Degludec is different.

At steady state, the terminal half-life of insulin degludec exceeds 25 hours, and its glucose-lowering effect persists for more than 42 hours 2. This means that even 24 hours after the last injection, circulating degludec concentrations remain well above zero. A single skipped dose produces a gradual rise in fasting glucose rather than the abrupt spike seen with shorter-acting basals. The flat, peakless profile also reduces hypoglycemia risk if the patient takes the missed dose later and the remaining drug from the prior injection overlaps 3.

A 26-week crossover trial (BEGIN FLEX T1) tested deliberate dose-timing variation. Patients injected degludec on a forced schedule that alternated 8-hour and 40-hour interdose intervals. Even with this extreme variability, HbA1c outcomes were non-inferior to fixed-time dosing 3. The rate of confirmed hypoglycemia did not differ significantly between the flexible and fixed-time arms (P = 0.58). That trial is the closest published evidence we have for what happens when a dose is substantially delayed.

Short sentence for emphasis: the drug was designed for forgiveness.

How Tresiba Works: Mechanism and Pharmacokinetics

Insulin degludec is a modified human insulin analog. At position B29, a 16-carbon fatty diacid side chain is attached via a glutamic acid spacer 2. In the pen cartridge, the drug exists as di-hexamers stabilized by phenol and zinc. After subcutaneous injection, phenol diffuses away and the di-hexamers self-associate into long multi-hexamer chains. These chains form a soluble depot under the skin.

Zinc then slowly diffuses out, causing individual hexamers to detach from the chain ends. Each hexamer dissociates into dimers, then monomers, which are absorbed into the capillary bed. The entire process takes more than 42 hours from a single injection, producing an absorption profile so flat that the coefficient of variation for day-to-day glucose-lowering effect is four times lower than that of glargine U100 4.

Once in circulation, degludec binds to the insulin receptor identically to native human insulin. It suppresses hepatic glucose output, promotes peripheral glucose uptake in muscle and adipose tissue, and inhibits lipolysis. The glucose-lowering mechanism is the same as any exogenous insulin. What differs is the delivery kinetics. That kinetic advantage is what makes a late or missed dose less dangerous with degludec than with other basal insulins.

Peak serum concentration is not clinically meaningful for degludec at steady state because there is no true peak. Plasma levels remain within a narrow band throughout the 24-hour dosing interval. This "peakless" profile was confirmed in clamp studies across both type 1 and type 2 diabetes populations 4.

What Happens Physiologically When You Miss a Dose

Missing one injection of degludec triggers a predictable sequence. For the first 8 to 12 hours, circulating insulin levels remain adequate because the subcutaneous depot from the previous day is still releasing monomers. Fasting glucose may remain near target or rise modestly by 20 to 40 mg/dL.

Between 12 and 24 hours after the missed dose window, the depot is meaningfully depleted. Hepatic glucose output begins rising as basal insulin coverage thins. In type 2 diabetes, endogenous insulin secretion partially compensates; fasting glucose may increase by 40 to 80 mg/dL but frank hyperglycemia above 300 mg/dL is uncommon from a single missed dose. In type 1 diabetes, the situation is more urgent because there is no endogenous reserve. Without correction, ketogenesis can begin within 6 to 12 hours once circulating insulin falls below a threshold.

After 24 to 42 hours, the prior depot is essentially exhausted. If no dose has been given, the patient is functionally without basal insulin, and the clinical picture resembles an insulin omission event: rising glucose, potential ketonuria, risk of diabetic ketoacidosis in type 1 patients.

This timeline underscores a key clinical point. A missed degludec dose in type 1 diabetes should be corrected within hours, not deferred to the next day. The 42-hour tail provides a buffer, not a holiday.

DEVOTE Trial: Safety Evidence Behind the Protocol

The DEVOTE trial (N = 7,637) was a cardiovascular outcomes study comparing insulin degludec with insulin glargine U100 in patients with type 2 diabetes at high cardiovascular risk 5. Published in the New England Journal of Medicine in 2017, it established two findings relevant to the missed-dose question.

First, degludec was non-inferior to glargine on three-point MACE (hazard ratio 0.91, 95% CI 0.78 to 1.06, P < 0.001 for non-inferiority) 5. Second, the rate of severe nocturnal hypoglycemia was 40% lower with degludec than with glargine (rate ratio 0.60, P = 0.004). That hypoglycemia advantage is directly tied to the flat pharmacokinetic profile that also makes dose-timing flexibility possible.

"The significantly lower rate of severe hypoglycemia with degludec, particularly at night, reflects its more stable pharmacokinetic and pharmacodynamic profile," the DEVOTE investigators wrote 5.

For the missed-dose scenario, this matters because the main risk of taking a late dose is hypoglycemia from dose overlap. If the drug's profile minimizes nocturnal lows even under normal conditions, the safety margin for a delayed injection is wider than with glargine.

Missed-Dose Protocol for Type 1 vs. Type 2 Diabetes

The FDA label does not differentiate the missed-dose rule by diabetes type. The instruction is the same: inject when remembered, maintain an 8-hour gap. But the clinical urgency is very different.

In type 2 diabetes, most patients retain some endogenous beta-cell function. Missing one basal dose may raise fasting glucose but rarely triggers ketoacidosis. The American Diabetes Association's Standards of Care note that patients on basal insulin alone (without bolus) have a lower hypoglycemia burden, and the primary risk of a missed dose is hyperglycemia, not a metabolic emergency 6.

In type 1 diabetes, the calculus shifts. Every hour without circulating insulin accelerates ketone production. The Endocrine Society's 2024 clinical practice guideline on type 1 diabetes management recommends that patients using ultra-long-acting basals like degludec should still carry rapid-acting insulin for correction doses when a basal injection is substantially delayed 7. If a type 1 patient realizes at hour 16 that the morning degludec was missed, taking it immediately is correct, but a correction bolus with rapid-acting insulin may also be needed if glucose is already above target.

A practical rule: type 2 patients can usually wait until they remember and simply inject. Type 1 patients should check blood glucose immediately upon realizing the dose was missed, inject the degludec, and correct with rapid-acting insulin if glucose exceeds their individualized target by more than 50 mg/dL.

Dosing Flexibility Studies: What the Data Actually Show

Three randomized trials directly tested degludec's dosing flexibility. The results define the boundaries of safe dose-timing variation.

BEGIN FLEX (type 2 diabetes, N = 687) randomized patients to either fixed-time degludec or a flexible schedule with a minimum 8-hour and maximum 40-hour gap between doses 8. After 26 weeks, HbA1c reduction was non-inferior in the flexible arm (estimated treatment difference 0.13%, 95% CI −0.01 to 0.27). Hypoglycemia rates were comparable.

BEGIN FLEX T1 extended this design to type 1 diabetes. Results were consistent: HbA1c remained non-inferior, and hypoglycemia rates did not differ between flexible and fixed dosing 3.

A third study by Heise et al. used glucose clamp methodology to measure intra-subject variability. The coefficient of variation for glucose-lowering effect was 20% for degludec versus 82% for glargine U100 over a 24-hour period 4. The four-fold difference in variability explains why flexible dosing is feasible with degludec but has never been formally studied or recommended for glargine.

These flexibility trials do not specifically model a "missed and then late" scenario. They model planned variation. A truly missed dose, where many hours pass before the patient realizes, introduces a longer gap than what was tested. The 42-hour duration of action provides a pharmacological buffer, but it is not unlimited, and patients should not interpret these data as permission to routinely skip doses.

When to Contact Your Provider After a Missed Dose

Most single missed doses of Tresiba can be self-managed using the protocol above. Contact your prescriber if any of these apply:

• Blood glucose exceeds 300 mg/dL and does not respond to a correction dose within 2 hours
• Urine or blood ketones are moderate or large (type 1 diabetes)
• You have missed two or more consecutive doses
• You are experiencing nausea, vomiting, or abdominal pain alongside hyperglycemia (signs of developing ketoacidosis)
• You are unsure whether your pen delivered a partial dose (mechanical malfunction)

The Novo Nordisk patient support line and the Tresiba prescribing information both recommend calling a healthcare provider before making any dose adjustment beyond the standard missed-dose instruction 1. This includes situations where the patient wants to temporarily increase their dose to "catch up." Dose doubling is never appropriate.

Preventing Missed Doses: Practical Strategies

The most effective intervention is a daily alarm set to the same time. A 2019 meta-analysis of adherence interventions in insulin-treated diabetes (17 RCTs, N = 3,841) found that simple reminder systems reduced missed doses by 23% compared with usual care 9.

Because Tresiba permits once-daily dosing at any time of day, patients can anchor the injection to an existing daily habit: morning coffee, brushing teeth before bed, or a consistent mealtime. The Endocrine Society recommends aligning insulin timing with a patient's most predictable daily routine rather than prescribing a rigid clock time 7.

Pen storage matters too. Tresiba pens in use can be kept at room temperature (below 30°C / 86°F) for up to 56 days 1. That 8-week window is twice as long as most insulin pens, which simplifies travel and reduces the chance that a patient skips a dose because the pen was left in a refrigerator at home.

For patients who travel across time zones, the 8-hour minimum interdose interval is the governing constraint. A patient flying from New York to London (5 hours ahead) can take their dose 5 hours earlier than usual on the arrival day and then resume local time the next day, provided the gap between the pre-flight dose and the arrival dose is at least 8 hours.

Tresiba vs. Other Basal Insulins: Missed-Dose Comparison

No other basal insulin on the U.S. market has published flexibility trial data. Glargine U100 (Lantus), glargine U300 (Toujeo), and detemir (Levemir) all carry label instructions to inject at the same time each day. Glargine U300 has a longer duration than U100 (approximately 30 to 36 hours), which provides some buffer, but Novo Nordisk is the only manufacturer that ran randomized trials specifically testing variable dosing times and incorporated the results into the approved label 1.

"Insulin degludec's unique multi-hexamer depot mechanism provides a duration of action exceeding 42 hours, which is the pharmacological basis for its approved dosing flexibility," notes the European Medicines Agency's assessment report on Tresiba 10.

This does not mean degludec is clinically superior to glargine U300 for every patient. The choice of basal insulin depends on formulary access, cost, and individual glycemic response. It does mean that for patients who frequently miss doses or have irregular schedules, degludec has the strongest evidence base for safe dose-timing variation.

Fasting glucose targets remain the same regardless of which basal insulin is prescribed: 80 to 130 mg/dL per ADA guidelines, with individualization based on age, comorbidities, and hypoglycemia risk 6.